Baricitinib for COVID-19

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Running title: Baricitinib for COVID-19

RECOVERY Collaborative Group*

*The Writing Committee and Trial Steering Committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix.

Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom.

Email: recoverytrial@ndph.ox.ac.uk

Baricitinib for COVID-19

SUMMARY

Background: We evaluated the use of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, for the treatment of patients admitted to hospital because of COVID-19.

Methods: This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised for COVID-19. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group). The primary outcome was 28-day mortality assessed in the intention-to-treat population. A meta-analysis was conducted that included the results from the RECOVERY trial and all previous randomised controlled trials of baricitinib or other JAK inhibitor in patients hospitalised with COVID-19. The RECOVERY trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

Findings: Between 2 February 2021 and 29 December 2021, 8156 patients were randomly allocated to receive usual care plus baricitinib versus usual care alone. At randomisation, 95% of patients were receiving corticosteroids and 23% receiving tocilizumab (with planned use within the next 24 hours recorded for a further 9%). Overall, 513 (12%) of 4148 patients allocated to baricitinib versus 546 (14%) of 4008 patients allocated to usual care died within 28 days (age-adjusted rate ratio 0.87; 95% CI 0.77-0.98; $p=0.026$). This 13% proportional reduction in mortality was somewhat smaller than that seen in a meta-analysis of 8 previous trials of a JAK inhibitor (involving 3732 patients and 425 deaths) in which allocation to a JAK inhibitor was associated with a 43% proportional reduction in mortality (rate ratio 0.57; 95% CI 0.45-0.72). Including the results

Baricitinib for COVID-19

from RECOVERY into an updated meta-analysis of all 9 completed trials (involving 11,888 randomised patients and 1484 deaths) allocation to baricitinib or other JAK inhibitor was associated with a 20% proportional reduction in mortality (rate ratio 0.80; 95% CI 0.71-0.89; $p < 0.001$). In RECOVERY, there was no significant excess in death or infection due to non-COVID-19 causes and no excess of thrombosis, or other safety outcomes.

Interpretation: In patients hospitalised for COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials. The total randomised evidence to date suggests that JAK inhibitors (chiefly baricitinib) reduce mortality in patients hospitalised for COVID-19 by about one-fifth.

Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056).

Keywords: COVID-19, baricitinib, clinical trial, meta-analysis.

Baricitinib for COVID-19

INTRODUCTION

In patients admitted to hospital with severe COVID-19, the host immune response is thought to play a key role in driving an acute inflammatory process resulting in hypoxic respiratory failure that may require mechanical ventilator support or lead to death.^{1,2} It has previously been shown that the use of dexamethasone and other corticosteroids reduces the risk of death in patients with severe hypoxic COVID-19 and that the addition of an interleukin-6 (IL-6) receptor blocker further reduces the risk of death in these patients.³⁻⁶

Baricitinib is an inhibitor of Janus kinase (JAK)1 and JAK2 that is licensed in the UK for the treatment of rheumatoid arthritis and atopic dermatitis. The JAKs are a family of four transmembrane protein kinases (JAK1, JAK2, JAK3 and TYK2) that mediate intracellular signalling of a range of extracellular cytokines and interferons.⁷ JAK inhibition prevents downstream phosphorylation and hence activation of signal transducers and activators of transcription (STAT). Since the JAK-STAT pathway mediates the effect of several cytokines, including IL-6, that are raised in severe COVID-19, JAK inhibitors have been proposed as a potential therapeutic option for severe COVID-19.^{8,9} Baricitinib also has moderate inhibitory activity against tyrosine kinase 2 (TYK2) and genetic data support a causal link between high TYK2 expression and life-threatening COVID-19.¹⁰ Baricitinib was also predicted, using artificial intelligence, to reduce endocytosis of SARs-CoV-2 into lung cells by inhibiting AP2-associated protein kinase 1 (AAK1) and cyclin G associated kinase (GAK).⁸

Baricitinib for COVID-19

Baricitinib was tested in combination with remdesivir in the Adaptive Covid-19 Treatment Trial-2 (ACTT-2) and was shown to improve time to recovery compared to remdesivir alone (rate ratio for recovery 1.16, 95% CI 1.01-1.32). There was also a suggestion that 28-day mortality may be reduced by baricitinib (HR 0.65, 95% CI 0.39-1.09).¹¹ As a consequence, the US Food and Drug Administration (US FDA) issued an emergency use authorisation for the use of baricitinib in combination with remdesivir, for the treatment of COVID-19 in hospitalised patients requiring oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).¹² Since then, a further 7 randomised trials of JAK inhibitors have reported,¹³⁻¹⁹ of which two have reported a significant reduction in mortality.^{16,19} Here we report the results of a large randomised controlled trial of baricitinib in patients hospitalised with severe COVID-19.

METHODS

Study design and participants

The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-initiated, individually randomised, controlled, open-label, platform trial to evaluate the effects of potential treatments in patients hospitalised with COVID-19. Details of the trial design and results for other possible treatments (dexamethasone, hydroxychloroquine, lopinavir-ritonavir, azithromycin, tocilizumab, convalescent plasma, colchicine, aspirin, and casirivimab plus imdevimab) have been published previously.^{3,5,20-26} The trial is underway at 177 hospital organisations in the United Kingdom supported by the National Institute for Health Research Clinical Research Network (appendix pp 3-27). Of these,

Baricitinib for COVID-19

159 UK hospitals took part in the evaluation of baricitinib. The trial is coordinated by the Nuffield Department of Population Health at the University of Oxford (Oxford, UK), the trial sponsor. The trial is conducted in accordance with the principles of the International Conference on Harmonisation–Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Cambridge East Research Ethics Committee (ref: 20/EE/0101). The protocol and statistical analysis plan are available in the appendix (pp 61-140) with additional information available on the study website www.recoverytrial.net.

Patients aged at least 2 years admitted to hospital were eligible for the study if they had clinically suspected or laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial. Patients were ineligible for the comparison of baricitinib vs. usual care if aged <2 years, eGFR <15 mL/min/1.73m² or on dialysis or haemofiltration, neutrophil count <0.5 x 10⁹/L, had evidence of active TB infection, or were pregnant or breastfeeding. Written informed consent was obtained from all patients, or a legal representative if patients were too unwell or unable to provide consent.

Randomisation and masking

Baseline data were collected using a web-based case report form that included demographics, level of respiratory support, major comorbidities, suitability of the study treatment for a particular patient, and treatment availability at the study site (appendix pp 36-38). Data on SARS-CoV-2 vaccination status were collected from 22 December 2020.

Baricitinib for COVID-19

Eligible and consenting patients were assigned in a 1:1 ratio to either usual standard of care plus baricitinib or usual standard of care alone, using web-based simple (unstratified) randomisation with allocation concealed until after randomisation (appendix pp 29-33). For some patients, baricitinib was unavailable at the hospital at the time of enrolment or was considered by the managing physician to be either definitely indicated or definitely contraindicated. These patients were excluded from the randomised comparison between baricitinib versus usual care. Patients allocated to baricitinib were to receive baricitinib 4 mg daily for 10 days (or until discharge if sooner). The dose was to be reduced for patients with eGFR <60 mL/min/1.73m² or receiving probenecid, and for children aged <9 years (see appendix p 28 for dosing details). Prior or subsequent administration of tocilizumab was permitted at the discretion of the managing doctor who was also responsible for considering the risk of infection and gastrointestinal perforation (particularly in the context of corticosteroid use).

As a platform trial, and in a factorial design, patients could be simultaneously randomised to other treatment groups: i) colchicine versus usual care, ii) aspirin versus usual care, iii) dimethyl fumarate versus usual care, iv) casirivimab+imdevimab versus usual care, and v) empagliflozin versus usual care. Further details of when these factorial randomisations were open are provided in the supplementary appendix (pp 29-33). Participants and local study staff were not masked to the allocated treatment. The Trial Steering Committee, investigators, and all other individuals involved in the trial were masked to outcome data during the trial.

Baricitinib for COVID-19

Procedures

An online follow-up form was completed by site staff when patients were discharged, had died, or at 28 days after randomisation, whichever occurred first (appendix pp 39-46). Information was recorded on adherence to allocated trial treatment, receipt of other COVID-19 treatments, duration of admission, receipt of respiratory or renal support, new cardiac arrhythmia, thrombosis, clinically significant bleeding, non-COVID infection, and vital status (including cause of death). In addition, routinely collected healthcare and registry data were obtained, including information on vital status at day 28 (with date and cause of death); discharge from hospital; and receipt of respiratory support or renal replacement therapy.

Outcomes

Outcomes were assessed at 28 days after randomisation, with further analyses specified at 6 months. The primary outcome was 28-day all-cause mortality. Secondary outcomes were time to discharge from hospital, and, among patients not on invasive mechanical ventilation at randomisation, the composite outcome of invasive mechanical ventilation (including extra-corporeal membrane oxygenation) or death. Prespecified subsidiary clinical outcomes were use of invasive or non-invasive ventilation among patients not on any ventilation at randomisation, time to successful cessation of invasive mechanical ventilation (defined as cessation of invasive mechanical ventilation within, and survival to, 28 days), and use of renal dialysis or haemofiltration. Prespecified safety outcomes were cause-specific mortality, major cardiac arrhythmia, thrombotic and major bleeding events, and other infections. Information on suspected serious adverse reactions was collected

Baricitinib for COVID-19

in an expedited fashion to comply with regulatory requirements. Details of the methods used to ascertain and derive outcomes are provided in the appendix (pp.141-161).

Statistical Analysis

For all outcomes, intention-to-treat analyses compared patients randomised to baricitinib with patients randomised to usual care. Through the play of chance in the unstratified randomisation, patients in the baricitinib group were slightly older than patients in the usual care group (Table 1). In accordance with the prespecified statistical analysis plan for dealing with baseline imbalances in important prognostic factors (appendix p 125), estimates of the effect of allocation to baricitinib on major outcomes were adjusted for age in three groups (<70 years, ≥ 70 to <80 years, and ≥ 80 years). (Exploratory analyses were conducted without this adjustment and, separately, with further adjustment for other predefined subgroups of interest.)

For the primary outcome of 28-day mortality, the hazard ratio from an age-adjusted Cox model was used to estimate the mortality rate ratio. We constructed Kaplan-Meier survival curves to display cumulative mortality over the 28-day period. We used the same method to analyse time to hospital discharge and successful cessation of invasive mechanical ventilation, with patients who died in hospital right-censored on day 29. Median time to discharge was derived from Kaplan-Meier estimates. For the pre-specified composite secondary outcome of progression to invasive mechanical ventilation or death within 28 days (among those not receiving invasive mechanical ventilation at randomisation), and the subsidiary clinical outcomes of receipt of ventilation and use of haemodialysis or

Baricitinib for COVID-19

haemofiltration, the precise dates were not available and so a log-binomial regression model was used to estimate the age-adjusted risk ratio. Estimates of rate and risk ratios (both denoted RR) are shown with 95% confidence intervals.

Prespecified analyses of the primary outcome were done in subgroups defined by six characteristics at the time of randomisation (age, sex, ethnicity, days since symptom onset, level of respiratory support, and use of corticosteroids) with tests of heterogeneity or trend, as appropriate. The full database is held by the study team which collected the data from study sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford (Oxford, UK).

The independent Data Monitoring Committee reviewed unblinded analyses of the study data and any other information considered relevant to the trial at intervals of around 2 to 4 weeks (depending on speed of enrolment) and was charged with determining if, in their view, the randomised comparisons in the study provided evidence on mortality that was strong enough (with a range of uncertainty around the results that was narrow enough) to affect national and global treatment strategies (see appendix p 50).

As stated in the protocol, appropriate sample sizes could not be estimated when the trial was being planned. On the advice of the Trial Steering Committee, recruitment to this comparison was closed on 29 December 2021 when over 8150 patients had been randomised and the blinded 28-day mortality rate was 12.9% (suggesting there would be at least 1050 deaths), giving at least 90% power to detect a proportional risk reduction in the primary outcome of one-fifth at $2P=0.01$. The Trial Steering Committee and all other

Baricitinib for COVID-19

211 individuals involved in the trial were masked to outcome data until after the close of
212 recruitment.

213 For the primary outcome of 28-day mortality, the results from the RECOVERY trial were
214 subsequently included in a meta-analysis of results from all previous randomised
215 controlled trials of a JAK inhibitor for patients hospitalised with COVID-19. Details of the
216 systematic search methods are provided in the appendix (p 28). For each trial, we
217 compared the observed number of deaths among patients allocated to the JAK inhibitor
218 with the expected number if all patients were at equal risk (i.e., we calculated the observed
219 minus expected statistic [o-e], and its variance v). For RECOVERY, these were estimated
220 from the age-adjusted mortality log rate ratio and its standard error but for other trials,
221 where the exact timing of each death was not available, these were calculated from
222 standard formulae for 2×2 contingency tables. We then combined trial results using the
223 log of the mortality rate ratio calculated as the inverse-variance-weighted average S/V
224 with variance $1/V$ (and hence with 95% CI $S/V \pm 1.96/\sqrt{V}$), where S is the sum over all
225 trials of (o-e) and V is the sum over all trials of v.²⁷ Such meta-analyses do not make any
226 assumptions about the nature of any true heterogeneity in the log RR between different
227 trials (in particular it does not assume that it is zero). Analyses were performed using SAS
228 version 9.4 and R version 4.0.3. The trial is registered with ISRCTN (50189673) and
229 clinicaltrials.gov (NCT04381936).

230 **Role of the funding source**

231 The funders of the study had no role in study design, data collection, data analysis, data
232 interpretation, or writing of the report. Baricitinib was provided from standard National

Baricitinib for COVID-19

Health Service (NHS) stocks. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

RESULTS

Between 2 February 2021 and 29 December 2021, 8156 (75%) of 10852 patients enrolled into the RECOVERY trial at one of the 169 participating sites were eligible to be randomly allocated to baricitinib (i.e. the treatment was available in the hospital at the time and the attending clinician was of the opinion that the patient had no known indication for or contraindication to it, figure 1). 4148 patients were randomly allocated to baricitinib and 4008 were randomly allocated to usual care. The mean age of study participants in this comparison was 58.1 years (SD 15.5) with a chance imbalance whereby patients randomly allocated to baricitinib were, on average, 0.8 years older than those allocated usual care group (Table 1). At randomisation, 7771 (95%) patients were receiving corticosteroids, 1872 (23%) were receiving tocilizumab (with planned use within the next 24 hours recorded for a further 756 [9%]) (Table 1, Webtable 1). About two-thirds were receiving simple oxygen and one quarter were receiving non-invasive ventilation, with small numbers receiving invasive mechanical ventilation or no respiratory support at all. 3420 (42%) patients had received at least one dose of a SARS-CoV-2 vaccine.

The follow-up form was completed for 4084 (98%) patients in the baricitinib group and 3950 (99%) patients in the usual care group. Among patients with a completed follow-up form, 91% allocated to baricitinib were reported to have received the treatment compared with <1% allocated to usual care (figure 1, webtable 2). Use of other treatments for

Baricitinib for COVID-19

COVID-19 was broadly similar among patients allocated baricitinib and among those allocated usual care, with nine-tenths receiving a corticosteroid, one-fifth receiving remdesivir, and one-tenth receiving casirivimab+imdevimab, although use of tocilizumab during the follow-up period was slightly lower in the baricitinib group than in the usual care group (26% vs. 29%) (webtable 2).

Primary and secondary outcome data are known for >99% of randomly assigned patients. Allocation to baricitinib was associated with a significant reduction in the primary outcome of 28-day mortality compared with usual care alone: 513 (12%) of 4148 patients in the baricitinib group died vs 546 (14%) of 4008 patients in the usual care group (age-adjusted rate ratio 0.87; 95% CI 0.77–0.98; $p=0.026$; table 2, figure 2). Similar proportional risk reductions were seen in sensitivity analyses adjusted for all pre-specified subgroups (as listed in figure 3) and without adjustment for the 0.8 year age-imbalance between randomised groups (webtable 3), and when restricted to participants with a positive SARS-CoV-2 PCR test (age adjusted RR 0.90, 95% CI 0.79-1.02).

The proportional effect of baricitinib on mortality was consistent across all pre-specified subgroups (Figure 3), including by level of respiratory support received (test for trend $p=0.33$), use of dexamethasone at randomisation (test for heterogeneity $p=0.41$) and, in exploratory analyses, by baseline CRP level (test for trend $p=0.93$) or by use of tocilizumab or remdesivir at baseline (tests for heterogeneity $p=0.53$ and $p=0.12$, respectively) (webfigure 1). There was no evidence that the effect of baricitinib on mortality varied depending on concurrent randomised allocation to colchicine, aspirin or casirivimab+imdevimab (all interaction p -values >0.32).

Baricitinib for COVID-19

277 Discharge alive within 28 days was more common among those allocated to baricitinib
278 compared with usual care (80% vs. 78%; age-adjusted rate ratio 1.10, 95% CI 1.04 to
279 1.15; median 8 days [IQR 5 to 17] vs. 8 days [IQR 5 to 20]) (table 2 and webfigure 2).
280 Among patients not on invasive mechanical ventilation at baseline, allocation to baricitinib
281 was associated with a lower risk of progressing to the composite secondary outcome of
282 invasive mechanical ventilation or death (16% vs. 17%, age-adjusted risk ratio 0.90, 95%
283 CI 0.81 to 0.99) (table 2 and webfigure 3). The proportional effects of baricitinib versus
284 usual care on these secondary outcomes were also similar across all pre-specified
285 subgroups (webfigures 2 and 3).

286 There were no significant differences in the pre-specified subsidiary clinical outcomes of
287 cause-specific mortality other than that due to COVID-19 (Webtable 4) or in use of
288 ventilation, successful cessation of invasive mechanical ventilation, or receipt of
289 haemodialysis or haemofiltration (table 2). There were no significant differences in the
290 rates of non-coronavirus infection, thrombotic events, or clinically significant bleeding, but
291 allocation to baricitinib was associated with a nominally significant reduction in new onset
292 cardiac arrhythmia (2.3% vs 3.1%, $p=0.017$) (webtable 5). There were 13 reports of a
293 serious adverse reaction believed to be related to treatment with baricitinib (webtable 6),
294 including 5 participants with a serious non-COVID infection, 3 with a bowel perforation
295 and 2 with a pulmonary embolism.

296 Our systematic search identified 8 previous trials of a JAK inhibitor for the treatment of
297 patients hospitalised with COVID-19, involving a total of 3732 randomised patients and
298 425 deaths (figure 4 and webtable 8).^{11,13-19} In these 8 trials, allocation to a JAK inhibitor
299 was associated with a significant 43% proportional reduction in mortality (rate ratio 0.57;

Baricitinib for COVID-19

95% CI 0.45-0.72). This was significantly greater than the mortality risk reduction seen in RECOVERY (test for heterogeneity, $p=0.001$). After inclusion of the results from RECOVERY into this meta-analysis, the average mortality rate ratio from all 9 trials, now involving 11,888 randomised patients and 1484 deaths, was 0.80 (0.71-0.89; $p<0.001$).

DISCUSSION

In this large, randomised trial, allocation to baricitinib significantly reduced 28-day mortality by about one-eighth. This is somewhat less than had been suggested by eight previous randomised, controlled trials of a JAK inhibitor which, together, suggested that allocation to a JAK inhibitor in COVID-19 patients reduces 28-day mortality by about two-fifths. RECOVERY was more than three times the size (in terms of statistical information) of these 8 previous trials put together. When combined in an updated meta-analysis, allocation to baricitinib or another JAK inhibitor in these 9 trials was associated with a significant reduction in 28-day mortality of one-fifth. Although not as large as perhaps previously thought, this still represents an important reduction in mortality risk for patients hospitalised because of COVID-19.

Strengths of the RECOVERY trial included that it was randomised, had a large sample size, broad eligibility criteria and more than 99% of patients were followed up for the primary outcome. The study has some limitations: this randomised trial is open label (i.e., participants and local hospital staff are aware of the assigned treatment), however, the outcomes are unambiguous and were ascertained without bias through linkage to routine health records. Use of tocilizumab during the follow-up period was slightly lower among

Baricitinib for COVID-19

those allocated to baricitinib compared with control (26% vs. 29%). Based on what we already know about the effects of tocilizumab, would, if anything, lead to a small underestimate of the effects of baricitinib. Furthermore, use of anti-viral or immunomodulatory treatments known to reduce mortality in this setting was similar in those allocated baricitinib and those allocated usual care. Information on radiological, virological or physiological outcomes was not collected.

The smaller effect size observed in RECOVERY compared to earlier trials of baricitinib may simply be a chance effect. However, several other factors could have contributed. The patient population in RECOVERY may have been broader than some of the other trials, which may have been enriched for patients more likely to benefit from immunomodulatory therapy. The use of concomitant therapies has varied between the trials. For example, the ACTT-2 trial did not permit the use of dexamethasone as a treatment for COVID-19, and ACTT-2, COV-BARRIER, RUXCOVID and the study by Guimaraes and colleagues all excluded the use of an IL-6 receptor blocker.^{11,15,16,18} Other factors that may be different between the trials include the prevalence of SARS-CoV-2 vaccination and the predominant circulating SARS-CoV-2 variant. However, there is no reason to believe that, among patients admitted to hospital with severe COVID-19 requiring oxygen or ventilatory support, the proportional risk reduction in mortality with baricitinib, a host-directed therapy, would differ by vaccination status or SARS-CoV-2 variant. Despite the heterogeneity of effect between RECOVERY and the previous 8 trials combined, the overall result of the meta-analysis (which makes no assumptions about the nature of any true differences in treatment effects between the different populations

Baricitinib for COVID-19

studied) provides the best guide of the proportional benefits that might be expected from the use of baricitinib in clinical practice.

The size of the RECOVERY trial allows exploration of the effects of treatment among different subgroups of patients. The benefits of baricitinib on 28-day mortality were consistent across all subgroups, including by age, sex, ethnicity, C-reactive protein, and level of respiratory support received (although over 90% participants were either on simple oxygen or receiving non-invasive mechanical ventilation). The benefits of baricitinib were also consistent regardless of concomitant treatment with remdesivir, a systemic corticosteroid and/or an IL-6 receptor blocker (tocilizumab or sarilumab). Reassuringly, we found no evidence that allocation to baricitinib was associated with excess rates of non-COVID mortality, non-COVID infection or thrombosis by comparison with usual care.

In November 2020, the US FDA granted Emergency Use Authorisation for baricitinib in combination with remdesivir and it has yet to receive marketing approval for COVID-19.¹² US National Institutes of Health guidelines updated in February 2022 recommend the use of baricitinib for patients on dexamethasone who have rapidly increasing oxygen needs and systemic inflammation.²⁸ In January 2022, the World Health Organization updated their COVID-19 therapeutics guidelines to include a strong recommendation for the use of baricitinib as an alternative to an IL-6 receptor blocker, in combination with corticosteroids, in patients with severe or critical COVID-19.²⁹ The results from the RECOVERY trial and our meta-analysis, considerably strengthen the evidence that baricitinib can reduce mortality and other adverse clinical outcomes in patients

Baricitinib for COVID-19

366 hospitalised with COVID-19 and support the co-administration of baricitinib with
367 dexamethasone and/or an IL-6 receptor blocker.

368 In summary, this large, randomised trial confirms evidence from previous smaller trials
369 that treatment with baricitinib can reduce mortality in patients hospitalised with COVID-
370 19, although the size of the benefit is about half that previously thought. The benefits
371 appear to be consistent regardless of treatment with remdesivir, systemic corticosteroids
372 and/or an IL-6 receptor blocker such as tocilizumab. The results support the use of
373 baricitinib in addition to other immunosuppressive therapies in patients hospitalised with
374 COVID-19.

375

Baricitinib for COVID-19

Research in context

Evidence before this study

We searched Medline, Embase, MedRxiv, bioRxiv and the WHO International Clinical Trials Registry Platform from Sept 1, 2019 to Feb 13, 2022, for randomised controlled trials evaluating the effect of baricitinib or another Janus Kinase (JAK) inhibitor in patients hospitalised with COVID-19 using the search terms (“SARS-CoV-2.mp” OR “SARS-CoV2” OR “SARSCoV2.mp” OR “COVID.mp” OR “COVID-19.mp” OR “COVID19.mp” OR “2019-nCoV.mp” OR “Coronavirus.mp” or “Coronavirinae/”) AND (“JAK inhibitor.mp or Janus kinase inhibitor/” OR “Janus kinase inhibitor.mp” OR “Baricitinib.mp or baricitinib/” OR terms for other specific JAK inhibitors (listed in appendix p 28) and using validated filters to select for randomised controlled trials. No language restrictions were applied.

We identified eight relevant randomised trials with results available that assessed JAK inhibitors in hospitalised patients with COVID-19: three assessed baricitinib, three assessed ruxolitinib and two assessed tofacitinib. Six of the trials had been fully published of which four were considered to be low risk of bias for the 28-day mortality outcome with two having some concerns (one because of lack of information about pre-specified analyses and some imbalances between randomised groups of other interventions given during the trial; the other because of lack of information about the randomisation process, inconsistency in reporting of outcome endpoint timing and lack of information about pre-specified analyses). A meta-analysis of these eight trials, which included a total of 425 deaths among 3732 patients, suggested that allocation to a JAK

Baricitinib for COVID-19

inhibitor was associated with a 43% proportional reduction in 28-day mortality (OR 0.57 [95% confidence interval 0.45-0.72]).

Added value of this study:

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is the largest randomised trial of the effect of a JAK inhibitor in patients hospitalised with COVID-19. We found that in 8156 patients admitted to hospital with COVID-19, baricitinib reduced 28-day mortality by 13%, increased the probability of discharge alive within 28 days, and, amongst patients who were not receiving invasive mechanical ventilation at randomisation, reduced the probability of progression to the composite outcome of invasive mechanical ventilation or death. The benefits were consistent in all subgroups of patients, including those receiving a systemic corticosteroid and/or an IL-6 receptor blocker.

Implications of all the available evidence:

The randomised evidence from all 9 completed JAK inhibitor trials to date suggest that treatment with baricitinib or an alternative JAK inhibitor reduces mortality by about one-fifth in hospitalised COVID-19 patients, including those already receiving a systemic corticosteroid and/or an IL-6 receptor blocker.

Baricitinib for COVID-19

Contributors

This manuscript was initially drafted by the PWH and MJL, further developed by the Writing Committee, and approved by all members of the Trial Steering Committee. PWH and MJL vouch for the data and analyses, and for the fidelity of this report to the study protocol and data analysis plan. PWH, MM, JKB, MB, LCC, JD, SNF, TJ, EJ, KJ, WSL, AMo, AMu, KR, RH, and MJL designed the trial and study protocol. MM, LP, MC, G P-A, CL, DRC, CB, RS, PC, AA, CAG, BP, TF, AK, and the Data Linkage team at the RECOVERY Coordinating Centre, and the Health Records and Local Clinical Centre staff listed in the appendix collected the data. NS and JRE did the statistical analysis. All authors contributed to data interpretation and critical review and revision of the manuscript. PWH and MJL had access to the study data and had final responsibility for the decision to submit for publication.

Writing Committee (on behalf of the RECOVERY Collaborative Group):

Peter W Horby,* Jonathan R Emberson,* Marion Mafham,* Mark Campbell, Leon Peto, Guilherme Pessoa-Amorim, Enti Spata, Natalie Staplin, Catherine Lowe, David R Chadwick, Christopher Brightling, Richard Stewart, Paul Collini, Abdul Ashish, Christopher A Green, Ben Prudon, Timothy Felton, Anthony Kerry, J Kenneth Baillie, Maya H Buch, Saul N Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Richard Haynes,+ Martin J Landray.+

* PWH, JRE and MM made an equal contribution

+ RH and MJL made an equal contribution

Data Monitoring Committee

Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo, Mohammed Munavvar, Adilia Warris, Janet Wittes.

Baricitinib for COVID-19

Declaration of interests

The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see <https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf>).

Data sharing

The protocol, consent form, statistical analysis plan, definition & derivation of clinical characteristics & outcomes, training materials, regulatory documents, and other relevant study materials are available online at www.recoverytrial.net. As described in the protocol, the Trial Steering Committee will facilitate the use of the study data and approval will not be unreasonably withheld. Deidentified participant data will be made available to bona fide researchers registered with an appropriate institution within 3 months of publication. However, the Steering Committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the study participants in the consent documentation and ethical approvals, and is compliant with relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Steering Committee will have the right to review and comment on any draft manuscripts prior to publication. Data will be made available in line with the policy and procedures described at: <https://www.ndph.ox.ac.uk/data-access>. Those wishing to request access should complete the form at https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx and e-mailed to: data.access@ndph.ox.ac.uk

Baricitinib for COVID-19

Acknowledgements

Above all, we would like to thank the thousands of patients who participated in this trial. We would also like to thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at 169 NHS hospital organisations across the whole of the UK, supported by staff at the National Institute of Health Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health & Social Care, the Intensive Care National Audit & Research Centre, Public Health Scotland, National Records Service of Scotland, the Secure Anonymised Information Linkage (SAIL) at University of Swansea, and the NHS in England, Scotland, Wales and Northern Ireland.

The RECOVERY trial is supported by grants to the University of Oxford from UK Research and Innovation (UKRI) and NIHR (MC_PC_19056), the Wellcome Trust (Grant Ref: 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator, and by core funding provided by the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill and Melinda Gates Foundation, the Foreign, Commonwealth and Development Office, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical Research Council (MC_UU_00002/14). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. Tocilizumab was provided free of charge for this trial by Roche Products Limited. Regeneron Pharmaceuticals supported the trial through provision of casirivimab and imdevimab. Baricitinib was provided from routine NHS stock. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Baricitinib for COVID-19

References

1. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *Bmj* 2020; **369**: m1985.
2. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med* 2020; **26**(10): 1636-43.
3. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med* 2021; **384**(8): 693-704.
4. Sterne JAC, Diaz J, Villar J, et al. Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials. *Trials* 2020; **21**(1): 734.
5. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2021; **397**(10285): 1637-45.
6. WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group, Shankar-Hari M, Vale CL, et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. *JAMA* 2021; **326**(6): 499-518.
7. Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. *Drugs* 2017; **77**(5): 521-46.
8. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. *Lancet* 2020; **395**(10223): e30-e1.
9. Stebbing J, Krishnan V, de Bono S, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. *EMBO Mol Med* 2020; **12**(8): e12697.
10. Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in COVID-19. *Nature* 2021; **591**(7848): 92-8.
11. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *New England Journal of Medicine* 2020; **384**(9): 795-807.
12. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19. 2020. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19> (accessed 21 Feb 2022).

Baricitinib for COVID-19

- 530 13. Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease
531 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. *J Allergy Clin*
532 *Immunol* 2020; **146**(1): 137-46.e3.
- 533 14. Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus
534 standard of care for the treatment of critically ill hospitalised adults with COVID-19 on
535 invasive mechanical ventilation or extracorporeal membrane oxygenation: an
536 exploratory, randomised, placebo-controlled trial. *Lancet Respir Med* 2022.
- 537 15. Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in Patients Hospitalized
538 with Covid-19 Pneumonia. *New England Journal of Medicine* 2021; **385**(5): 406-15.
- 539 16. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for
540 the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised,
541 double-blind, parallel-group, placebo-controlled phase 3 trial. *The Lancet Respiratory*
542 *Medicine* 2021; **9**(12): 1407-18.
- 543 17. Murugesan H, Cs G, Nasreen HS, et al. An Evaluation of Efficacy and Safety of
544 Tofacitinib, A JAK Inhibitor in the Management of Hospitalized Patients with Mild to
545 Moderate COVID-19 - An Open-Label Randomized Controlled Study. *J Assoc*
546 *Physicians India* 2022; **69**(12): 11-2.
- 547 18. National Institutes of Health US National Library of Medicine Cg, NCT04362137.
548 Study to Assess the Efficacy and Safety of Ruxolitinib in Patients with COVID-19
549 associated cytokine storm (RUXCOVID) - Study results.
550 <https://clinicaltrials.gov/ct2/show/results/NCT04362137> (accessed 21 Feb 2022).
- 551 19. National Institutes of Health US National Library of Medicine Cg, NCT04377620,.
552 Assessment of Efficacy and Safety of Ruxolitinib in Participants with COVID-19-
553 Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) - Study
554 results. <https://clinicaltrials.gov/ct2/show/results/NCT04377620> (accessed 22 Feb
555 2022).
- 556 20. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of
557 Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020;
558 **383**(21): 2030-40.
- 559 21. RECOVERY Collaborative Group, Horby PW, Mafham M, et al. Lopinavir-
560 ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,
561 controlled, open-label, platform trial. *Lancet* 2020; **396**(10259): 1345-52.
- 562 22. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital
563 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
564 *Lancet* 2021; **397**(10274): 605-12.
- 565 23. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to
566 hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform
567 trial. *Lancet* 2021; **397**(10289): 2049-59.

Baricitinib for COVID-19

- 568 24. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with
569 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The*
570 *Lancet Respiratory Medicine* 2021.
- 571 25. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with
572 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*
573 2022; **399**(10320): 143-51.
- 574 26. RECOVERY Collaborative Group. Casirivimab and imdevimab in patients
575 admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-
576 label, platform trial. *Lancet* 2022; **399**(10325): 665-76.
- 577 27. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast
578 cancer: worldwide evidence 1985–1990. Oxford: Oxford University Press; 1990.
- 579 28. NIH. Therapeutic Management of Hospitalized Adults With COVID-19. 24 Feb
580 2022. [https://www.covid19treatmentguidelines.nih.gov/management/clinical-](https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/)
581 [management/hospitalized-adults--therapeutic-management/](https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/) (accessed 28 Feb 2022).
- 582 29. WHO. Therapeutics and COVID-19: living guideline. V9.2. 14 Jan 2022.
583 <https://app.magicapp.org/#/guideline/nBkO1E/rec/E5AOaN> (accessed 25 Feb 2022).
584

Table 1: Baseline characteristics by treatment allocation

	Treatment allocation	
	Baricitinib (n=4148)	Usual care (n=4008)
Age, years	58.5 (15.4)	57.7 (15.5)
<70	3142 (76%)	3086 (77%)
≥70 to <80	665 (16%)	655 (16%)
≥80	341 (8%)	267 (7%)
Sex		
Male	2740 (66%)	2638 (66%)
Female	1408 (34%)	1370 (34%)
Ethnicity		
White	3192 (77%)	3104 (77%)
Black, Asian, and minority ethnic	457 (11%)	455 (11%)
Unknown	499 (12%)	449 (11%)
Number of days since symptom onset	9 (6-12)	9 (6-11)
Number of days since admission to hospital	1 (1-3)	1 (1-3)
Respiratory support received		
None	228 (5%)	237 (6%)
Simple oxygen	2770 (67%)	2743 (68%)
Non invasive ventilation	1016 (24%)	911 (23%)
Invasive mechanical ventilation	134 (3%)	117 (3%)
Laboratory measurements		
CRP, mg/L	84 (42-146)	87 (44-143)
Creatinine, umol/L	76 (63-93)	77 (63-94)
Previous diseases		
Diabetes	961 (23%)	941 (23%)
Heart disease	782 (19%)	706 (18%)
Chronic lung disease	882 (21%)	783 (20%)
Tuberculosis	0 (0%)	0 (0%)
HIV	13 (<1%)	9 (<1%)
Severe liver disease *	33 (<1%)	33 (<1%)
Severe kidney impairment †	101 (2%)	79 (2%)
Any of the above	1957 (47%)	1834 (46%)
SARS-CoV-2 PCR test result		
Positive	3750 (90%)	3655 (91%)
Negative	50 (1%)	39 (<1%)
Unknown	348 (8%)	314 (8%)
Received a COVID-19 vaccine	1755 (42%)	1665 (42%)
Use of other treatments		
Corticosteroids	3962 (96%)	3809 (95%)
Remdesivir	878 (21%)	789 (20%)
Tocilizumab	951 (23%)	921 (23%)
Plan to use tocilizumab within the next 24 hours	391 (9%)	365 (9%)
Other randomly assigned treatments		
Colchicine	401 (10%)	401 (10%)
Aspirin	462 (11%)	453 (11%)
Casirivimab-imdevimab	440 (11%)	449 (11%)

Data are mean (SD), n (%), or median (IQR). 33 children and no pregnant women were randomised. 2 post-partum women were randomised to baricitinib *Defined as requiring ongoing specialist care. †Defined as estimated glomerular filtration rate <30 mL/min/1.73 m²

Table 2: Effect of allocation to baricitinib on key study outcomes

	Treatment allocation		RR (95% CI)	p-value
	Baricitinib (n=4148)	Usual care (n=4008)		
Primary outcome				
28-day mortality	513 (12%)	546 (14%)	0.87 (0.77-0.98)	0.026
Secondary outcomes				
Median (IQR) time to being discharged alive, days	8 (5 to 17)	8 (5 to 20)		
Discharged from hospital within 28 days	3337 (80%)	3137 (78%)	1.10 (1.04-1.15)	<0.001
Receipt of invasive mechanical ventilation or death*	631/4014 (16%)	670/3891 (17%)	0.90 (0.81-0.99)	0.026
Invasive mechanical ventilation	283/4014 (7%)	322/3891 (8%)	0.87 (0.74-1.01)	0.06
Death	475/4014 (12%)	502/3891 (13%)	0.89 (0.80-1.00)	0.049
Subsidiary clinical outcomes				
Receipt of ventilation †	595/2998 (20%)	637/2980 (21%)	0.93 (0.84-1.03)	0.17
Non-invasive ventilation	585/2998 (20%)	623/2980 (21%)	0.94 (0.85-1.04)	0.20
Invasive mechanical ventilation	131/2998 (4%)	148/2980 (5%)	0.90 (0.71-1.13)	0.35
Successful cessation of invasive mechanical ventilation ‡	61/134 (46%)	43/117 (37%)	1.28 (0.86-1.89)	0.22
Use of haemodialysis or haemofiltration §	85/4140 (2%)	109/4003 (3%)	0.77 (0.58-1.01)	0.06

Data are n (%) or n/N (%), unless otherwise indicated. RR=rate ratio for the outcomes of 28-day mortality, hospital discharge and successful cessation of invasive mechanical ventilation, and risk ratio for other outcomes. CI=confidence interval.

Estimates of the RR and its 95% CI are adjusted for age in three categories (<70 years, 70-79 years, and 80 years or older).

* Analyses exclude those on invasive mechanical ventilation at randomisation. † Analyses exclude those on any form of ventilation at randomisation. ‡ Analyses restricted to those on invasive mechanical ventilation at randomisation. § Analyses exclude those on haemodialysis or haemofiltration at randomisation.

Figure 1: Trial profile

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.02.22271623>; this version posted March 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

ITT=intention to treat. Baricitinib unavailable and baricitinib unsuitable groups are not mutually exclusive.

*Number recruited overall during the period that adult participants could be recruited into the baricitinib comparison.

Figure 2: Effect of allocation to baricitinib on 28-day mortality

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.02.22271623>; this version posted March 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

RR=age-adjusted rate ratio

Figure 3: Effect of allocation to baricitinib on 28-day mortality by pre-specified baseline characteristics

Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to 95% CIs. The days since onset and use of corticosteroids subgroups exclude patients with missing data, but these patients are included in the overall summary diamond. RR=age adjusted rate ratio.

Figure 4: JAK inhibitor vs usual care in patients hospitalised with COVID – Meta-analysis of mortality in RECOVERY and other trials

O-E=observed-expected. Var=variance. RR=Ratio of death rates. Details of the individual studies, including the use of placebo or other treatments in the control group are shown in Webtable 7.

* For RECOVERY, the O-E and its variance are calculated from the age-adjusted log RR and its standard error. For the other trials the O-E statistics and their variances are calculated from 2x2 tables. RR is calculated by taking $\ln RR$ to be $(O-E)/V$ with Normal variance $1/V$. Subtotals or totals of (O-E) and of V yield inverse-variance-weighted averages of the $\ln RR$ values without making any assumptions about the true heterogeneity in RRs between trials.

** For balance, controls in the n:1 studies count n times in the control totals and subtotals, but count only once when calculating their O-E and V values.

*** These trials did not assess baricitinib but assessed another JAK inhibitor. Restricting the meta-analysis to RECOVERY plus the 3 other baricitinib trials the RR would be 0.81 (95% CI 0.73–0.91).